A carregar...
Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renal-cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC, c...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5656352/ https://ncbi.nlm.nih.gov/pubmed/29089775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145295 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|